ClinicalTrials.gg
Not yet recruitingNCT07271745MAP-UHFUpdated Dec 9, 2025

Multicenter Study on Early Arterial Changes in Prediabetic Patients Evaluated by Ultra-High-Frequency Ultrasound

An observational study in Prediabetes, sponsored by Chunyan Ma. Not yet recruiting at 30 sites in China. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-09.

Sponsored by Chunyan Ma · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
1,740
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Prediabetic State with a site in China — 24 open to participants now, 25 under way, 1 of them phase 3. Prediabetic State · China.

Started
2025
with 9 others
Observational
7 of 51
5 open now
Primary completion
2026-12
later than 8 of 24 live
Registered
40th of 51
by date

Among the 51 studies in Prediabetic State with a site in China, this one is one of 10 that started in 2025, is one of 7 observational ones, reaches primary completion later than 8 of the 24 other live ones, and was the 40th registered.

Prediabetic State

919 studies on the registry are indexed under Prediabetic State; 231 are open to participants now.

Browse Prediabetic State studies →

Open to participants now

24 of the 51 studies in Prediabetic State with a site in China are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 144 Prediabetic State studies recruiting now, 51 (35%) set no upper age limit and 83 (58%) stop at 75 or younger; 12 take children under 18; 54 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Prediabetic State with a site in China, or all of them as a file.
02

Study summary

Ultra-high frequency ultrasound technology (20-100 MHz) can clearly distinguish the arterial intima and media layers, and can simultaneously meet the needs of examining the carotid artery and peripheral arteries, enabling earlier and more accurate detection of vascular damage in pre-diabetic individuals. Therefore, this study aims to establish the normal values of arterial intima and media thickness measured by ultra-high frequency ultrasound in healthy Chinese adults, providing quantitative reference for the early diagnosis, severity assessment, and efficacy observation of arterial diseases. Meanwhile, by applying ultra-high frequency ultrasound, this study intends to clarify the changes in arterial intima and media thickness in pre-diabetic populations and explore the influencing factors, so as to provide reference for the early prevention, diagnosis, and treatment of pre-diabetes and cardiovascular complications.

Read the detailed description

The arterial wall consists of the intima, media, and adventitia from inside to outside. Among them, intima-media thickness (IMT) is an important criterion for reflecting subclinical arteriosclerosis. However, this composite index has certain limitations. The pathological changes of atherosclerosis mainly occur in the intima, while hypertension, diabetes, etc., mainly affect the media. Therefore, measuring the thickness of the arterial intima and media separately can reflect the degree of vascular lesions in different diseases earlier and more accurately than IMT, which is of great clinical significance. However, there are currently no normal reference values for the thickness of the arterial intima and media.

Diabetes is one of the fastest-growing global public health events in the 21st century, with its prevalence and mortality rate ranking among the top of various diseases. Diabetes is also one of the diseases with the most complications, among which cardiovascular complications cause the greatest harm to patients and have become the leading cause of death in such patients. The vast majority of patients go through a pre-diabetic stage before developing clinically diagnosed diabetes. Epidemiological survey results show that the number of patients in the pre-diabetic stage is much larger than that of diabetic patients. In addition, before diabetes is diagnosed, hyperglycemia may have already caused vascular damage, first leading to thickening and calcification of the arterial media. Studies have shown that the prevalence of vascular calcification in pre-diabetic patients is much higher than that in non-diabetic patients. Early detection of medial vascular calcification is of great clinical value for evaluating vascular changes in pre-diabetes and thus enabling early prevention. However, there is a lack of relevant studies confirming the vascular lesions in pre-diabetes.

In the past, the ultrasound probes used for clinical examination of the carotid artery and peripheral arteries were mainly 5-10 MHz, with a resolution of 200-400 μm, which cannot clearly display the fine structure of the arterial wall, making it difficult to measure the intima or media alone. With the development of modern medical technology, the emergence of ultra-high frequency ultrasound (20-100 MHz) can clearly distinguish the arterial intima and media, and can simultaneously meet the needs of examining the carotid artery and peripheral arteries. It is expected to reflect vascular lesions caused by different diseases more sensitively and accurately, providing a new and beneficial tool for clinical observation of arterial structure.

In recent years, the ultra-high frequency ultrasound technology (20-100 MHz) has emerged, which can clearly distinguish the arterial intima and media, and can simultaneously meet the needs of examining the carotid artery and peripheral arteries, enabling earlier and more accurate detection of vascular damage in pre-diabetes. Therefore, our center has initiated this multi-center clinical research project, joining hands with multiple ultrasound centers across the country, aiming to establish the normal values of arterial intima and media thickness measured by ultra-high frequency ultrasound in healthy Chinese adults, providing quantitative reference for the early diagnosis, degree assessment, and efficacy observation of arterial diseases. At the same time, it aims to use ultra-high frequency ultrasound to clarify the changes in arterial intima and media thickness in pre-diabetic populations, explore the influencing factors, and provide reference for the early prevention, diagnosis, and treatment of pre-diabetes and cardiovascular complications.

03

Conditions studied

  • Prediabetes

Browse trials for

Keywords

  • Ultra-High-Frequency Ultrasound
  • Prediabetic
  • Arterial Changes
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

A total of 300 prediabetic patients were selected from the physical examination center and outpatient department, and 1,440 healthy subjects were enrolled.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Prediabetic Patients

Inclusion criteria

Inclusion Criteria:

  • Impaired fasting glucose (venous plasma glucose ≥6.1 mmol/L, \<7.0 mmol/L, and \<7.8 mmol/L 2 hours after glucose loading); and/or Impaired glucose tolerance (venous plasma glucose \<7.0 mmol/L, and ≥7.8 mmol/L, \<11.1 mmol/L 2 hours after glucose loading).
  • Age ≥ 18 years old;
  • Normal blood pressure (139-90/89-60 mmHg);
  • (BMI) \< 30 kg/m²;
  • Normal results in routine blood tests, fasting blood glucose, lipid profile, liver and kidney function tests, and (ECG);
  • No history of cardiovascular diseases, diabetes, rheumatic connective tissue diseases, or severe liver/kidney dysfunction;
  • No history of acrocyanosis, no discomfort under cold stimulation, and no previous Raynaud's phenomenon in any part of the body;
  • No history of taking medications that affect the cardiovascular system.

Exclusion criteria

Exclusion Criteria :

  • Patients with hypertension, diabetes mellitus, hyperthyroidism, arrhythmia, etc.
  • Patients with connective tissue diseases such as systemic lupus erythematosus, polymyositis, rheumatoid arthritis, etc.
  • History of blood diseases, severe infections, or other systemic diseases.
  • Administration of vasoactive drugs within the past month.
  • Peripheral vascular diseases with arterial occlusion that prevents detection of blood flow signals.
  • Inability to cooperate with the examination.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
1,740 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Healthy control group

    According to the criteria for establishing normal values, a total of 1,440 healthy Chinese adults were enrolled, stratified by gender and age, with 720 males and 720 females.

  • Prediabetic Patients group

    Patients meeting the 2019 WHO diagnostic criteria for prediabetes: impaired fasting glucose (venous plasma glucose ≥6.1 mmol/L, \<7.0 mmol/L, and \<7.8 mmol/L after glucose loading) and/or impaired glucose tolerance (venous plasma glucose \<7.0 mmol/L, and ≥7.8 mmol/L, \<11.1 mmol/L after glucose loading). A total of 300 prediabetic patients were included.

06

What researchers measure

Primary outcomes

  1. Measure the thickness of the arterial intima (mm), media (mm), and intima-media (mm) respectively

    Measuring the thickness of the arterial intima and media separately can more early and accurately reflect the degree of vascular lesions in different diseases.

    Time frame: 1 day

07

Study locations

30 sites
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Guangzhou, Guangdong, China
    • Jing Tian · Contact
  • The First Affiliated Hospital of Sun Yat-sen University
    Guangzhou, Guangdong, China
    • Yanling Zheng · Contact
  • The First Affiliated Hospital of Guangxi University of Chinese Medicine
    Nanning, Guangxi, China
    • Xueling Liu · Contact
  • The First Affiliated Hospital of Heilongjiang University of Chinese Medicine
    Harbin, Heilongjiang, China
    • Yanling Che · Contact
  • The Second Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang, China
    • Xiaoping Leng, PhD · Contact
  • The Second Hospital of Heilongjiang Province
    Harbin, Heilongjiang, China
    • Hong Ding · Contact
  • Jiamusi Central Hospital, Heilongjiang Province
    Jiamusi, Heilongjiang, China
  • Henan Provincial People's Hospital
    Zhengzhou, Henan, China
    • Haohui Zhu, PhD · Contact
  • Jiangsu Provincial People's Hospital
    Nanjing, Jiangsu, China
    • Ao Li · Contact
  • The Second Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi, China
    • Chunquan Zhang · Contact
  • China-Japan Union Hospital of Jilin University
    Changchun, Jinlin, China
    • Hui Wang · Contact
  • The First Hospital of Jilin University
    Changchun, Jinlin, China
    • Xiaofeng Sun · Contact
  • Anshan Central Hospital
    Anshan, Liaoning, China
    • Naihua Zhang · Contact
  • Chaoyang Central Hospital
    Chaoyang, Liaoning, China
    • Dena Hong · Contact
  • The First Affiliated Hospital of Dalian Medical University
    Dalian, Liaoning, China
    • Xiukun Hou, PhD · Contact
  • The Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
    Shenyang, Liaoning, China
    • Linwei Hong · Contact
  • Tongliao People's Hospital of Inner Mongolia Autonomous Region
    Tongliao, Neimenggu, China
    • Li Yang · Contact
  • Qilu Hospital (Qingdao Branch) of Shandong University
    Qingdao, Shandong, China
    • Li Li · Contact
  • West China Hospital,Sichuan University
    Chengdu, Sichuan, China
    • Xiaorong Wen · Contact
  • The First Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan, China
    • Yu Wang · Contact
  • The First People's Hospital of Yunnan Province
    Kunming, Yunnan, China
    • Fugang Mao · Contact
  • The Third People's Hospital of Yunnan Province
    Kunming, Yunnan, China
    • Rongping Ning · Contact
  • The Second People's Hospital of Qujing City
    Qujing, Yunnan, China
    • Renquan Wang · Contact
  • Li Huili Hospital of Ningbo Medical Center, Zhejiang Province
    Ningbo, Zhejing, China
    • Caiping Zou · Contact
  • Beijing Hospital
    Beijing, 100000, China
    • Junhong Ren, PhD · Contact
  • Beijing Tiantan Hospital, Capital Medical University
    Beijing, 100000, China
    • Wen He · Contact
  • Jiading District Central Hospital of Shanghai Municipality
    Shanghai, China
    • Yingchun Wang · Contact
  • Renji Hospital, Shanghai Jiao Tong University School of Medicine
    Shanghai, China
    • Lixin Jiang · Contact
  • Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine
    Shanghai, China
    • Wenfeng Xiong · Contact
  • The Third Central Hospital of Tianjin
    Tianjin, China
    • Yanmin Kan · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2025; primary completion for Dec 2026, 12 months later.

Of 48 observational studies under Prediabetic State, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 24. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2025
First posted
Dec 9, 2025
StartEst.
Dec 15, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Dec 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07271745
Lead sponsor
Chunyan Ma
Collaborators
Henan Provincial People's Hospital, Beijing Tiantan Hospital
Responsible party
Chunyan Ma (Chief of Cardiovascular Ultrasound, First Hospital of China Medical University) — Sponsor-investigator
First posted
Dec 9, 2025
Start date
Dec 15, 2025 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Dec 9, 2025

Study contacts

Chunyan Ma, Ph.D.
Contact
cmu1h_mcy@126.com
86+13998816448
Guangyuan Li, PhD candidate
Contact
604221697@@qq.com
86-15140191401
Chunyan Ma, Ph.D.
principal investigator · First Hospital of China Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion